Skip Navigation



European Heart Journal Advance Access published online on October 12, 2007
European Heart Journal, doi:10.1093/eurheartj/ehm435
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
28/21/2565    most recent
ehm435v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Duncker, D. J.
Right arrow Articles by Giessen, W. J. V. d.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Duncker, D. J.
Right arrow Articles by Giessen, W. J. V. d.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2007. For permissions please email: journals.permissions@oxfordjournals.org

Fat is not all bad: how to make good use of adipose tissue

Dirk J. Duncker*, André Uitterdijk and Wim J. Van der Giessen

Experimental Cardiology, Thoraxcenter, Cardiovascular Research Institute COEUR, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands

* Corresponding author. Tel: +31-10-4638066; fax: +31-10-4089494. E-mail address: d.duncker@erasmusmc.nl

This editorial refers to ‘Intracoronary administration of autologous adipose tissue-derived stem cells improves left ventricular function, perfusion, and remodelling after acute myocardial infarction’ by C. Valina et al., doi:10.1093/eurheartj/ehm426.

The first 10% of the full text of this article appears below.

Myocardial infarction (MI) continues to represent a major health problem. Improved healing and/or regeneration of infarcted myocardium by injection of progenitor cells has been proposed as a promising approach to prevent cardiac remodelling or even restore myocardial tissue. Several adult stem cell types have shown efficacy in the preclinical setting, including skeletal myoblasts, umbilical cord cells, bone marrow-derived mononuclear cells, and, more recently, adipose tissue-derived stem cells.1,2 Although the debate as to which cell type (or combinations thereof) is best suited for the treatment of acute MI continues, the mesenchymal stem cell (MSC)3 is particularly interesting. Thus, MSCs have been shown to be multipotent, to be capable of homing to infarcted myocardium, inducing angiogenesis and differentiating into myogenic cells, can be easily expanded ex vivo, and are possibly immune privileged.1–4 MSCs can be isolated from several organs, including bone marrow, umbilical cord blood, and adipose tissue, of which . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Intracoronary administration of autologous adipose tissue-derived stem cells improves left ventricular function, perfusion, and remodelling after acute myocardial infarction
Christian Valina, Kai Pinkernell, Yao-Hua Song, Xiaowen Bai, Sanga Sadat, Richard J. Campeau, Thierry H. Le Jemtel, and Eckhard Alt
EHJ 2007 28: 2667-2677. [Abstract] [FREE Full Text]